Gamma-Knife Surgery is Effective in Normalising Plasma Insulin-Like Growth Factor I in Patients with Acromegaly

Abstract

Objective: For patients in whom acromegaly persists despite pituitary surgery or drug treatment, gamma-knife surgery represents an additional treatment option. Considering carefully the different reported biochemical outcomes, the central point is whether gamma-knife radiosurgery has advantages compared to conventional radiotherapy or, furthermore, to newer medical therapies, such as long-acting somatostatin analogues or growth hormone receptor antagonists. Design and Methods: We report the outcome of 44 patients with acromegaly, who received gamma-knife surgery with the Leksell gamma knife. The median follow-up time was 1.9 years (0.5 - 4.3 years) post-radiosurgery. 43 of 44 patients had previously undergone pituitary surgery. Results: Immediately prior to gamma-knife surgery, median xULN of patients' serum IGF-I was 1.9 times above upper limit of normal (range: 0.5 - 8.9 xULN [multiple of upper limit of normal range]). There was a significant decline of serum IGF-I at patients' final follow-up. We found a normal age-adjusted IGF‐I in 21/44 patients (xULN of IGF-I < 1). Furthermore, as the number of treated patients increased, we found an improvement in remission rate, which let us assume that there was a learning effect for the gamma-knife performing team over time. In addition, the median adenoma size decreased from 1.5 ml (0.1 - 6.9 ml) prior to gamma-knife therapy to 0.3 ml (no rest vol. detectable - 2.4 ml) at patients' last visit. Conclusion: We have shown that pituitary gamma-knife surgery is effective in lowering serum IGF-I levels. At the end of the follow-up period, 48 % of our cohort had normal age-adjusted IGF‐I levels.

Acromegaly - gamma-knife surgery - irradiation

Literature

• 1 Abe T, Ludecke D K. Recent results of secondary transnasal surgery for residual or recurring acromegaly.  Neurosurg. 1998;  42 1013-1021 1021-1022 (discussion)
• 2 Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L, Cozzi R, Farabola M, Loli P, Beck-Peccoz P, Arosio M. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study.  J Clin Endocrinol Metab. 2003;  88 3105-3112
• 3 Ayuk J, Clayton R N, Holder G, Sheppard M C, Stewart P M, Bates A S. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.  J Clin Endocrinol Metab. 2004;  89 1613-1617
• 4 Barkan A L, Halasz I, Dornfeld K J, Jaffe C A, Friberg R D, Chandler W F, Sandler H M. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly.  J Clin Endocrinol Metabolism. 1997;  82 3187-3191
• 5 Bates A S, Van't Hoff W, Jones J M, Clayton R N. An audit of outcome of treatment in acromegaly.  Q J Med. 1993;  86 293-299
• 6 Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly.  Clin Endocrinol. 2003;  58 86-91
• 7 Giustina A, Barkan A, Casanueva F F, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S. Criteria for cure of acromegaly: a consensus statement.  J Clin Endocrinol Metab. 2000;  85 526-529
• 8 Gutt B, Hatzack C, Morrison K, Pollinger B, Schopohl J. Conventional pituitary irradiation is effective in normalising plasma IGF-I in patients with acromegaly.  Eur J Endocrinol. 2001;  144 109-116
• 9 Hardy J. Transsphenoidal surgery of hypersecreting pituitary tumors. Kohler PO, Ross GT Diagnosis and Treatment of Pituitary Tumors. New York; Elsevier Publishing Co. Inc 1973: 179-194
• 10 Hayashi M, Izawa M, Hiyama H, Nakamura S, Atsuchi S, Sato H, Nakaya K, Sasaki K, Ochiai T, Kubo O, Hori T, Takakura K. Gamma knife radiosurgery for pituitary adenomas.  Stereotact Funct Neurosurg. 1999;  72 111-118
• 11 Holdaway I M, Rajasoorya R C, Gamble G D. Factors influencing mortality in acromegaly.  J Clin Endocrinol Metab. 2004;  89 667-674
• 12 Kurosaki M, Luedecke D K, Abe T. Effectiveness of secondary transnasal surgery in GH-secreting pituitary macroadenomas.  Endocr J. 2003;  50 635-642
• 13 Landolt A M, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, Wellis G. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy.  J Neurosurg. 1998;  88 1002-1008
• 14 Landolt A M, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, Wellis G. Octreotide may act as a radioprotective agent in acromegaly.  J Clin Endocrinol Metab. 2000;  85 1287-1289
• 15 Laws Jr E R, Vance M L. Radiosurgery for pituitary tumors and craniopharyngiomas.  Neurosurg Clin N Am. 1999;  10 327-336
• 16 Lim Y L, Leem W, Kim T S, Rhee B A, Kim G K. Four years' experiences in the treatment of pituitary adenomas with gamma knife radiosurgery.  Stereotact Funct Neurosurg. 1998;  70 95-109
• 17 Melmed S. Acromegaly.  New Engl J Med. 1990;  322 966-977
• 18 Merza Z. Modern treatment of acromegaly.  Postgrad Med J. 2003;  79 189-194
• 19 Mokry M, Ramschak-Schwarzer S, Simbrunner J, Ganz J C, Pendl G. A six-year experience with the postoperative radiosurgical management of pituitary adenomas.  Stereotact Funct Neurosurg. 1999;  72 88-100
• 20 Morange-Ramos I, Regis J, Dufour H, Andrieu J M, Grisoli F, Jaquet P, Peragut J C. Gamma-knife surgery for secreting pituitary adenomas.  Acta Neurochir. 1998;  140 437-443
• 21 Powell J S, Wardlaw S L, Post K D, Freda P U. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure.  J Clin Endocrinol Metab. 2000;  85 2068-2071
• 22 Sheppard M C. Aims of treatment and definition of case. Wass JAH Treating Acromegaly. Bio Scientifica Ltd. Bristol, UK; Society for Endocrinology 1994: 17-23
• 23 Thoren M, Rahn T, Guo W Y, Werner S. Stereotactic radiosurgery with the cobalt-60 gamma unit in the treatment of growth hormone-producing pituitary tumors.  Neurosurg. 1991;  29 663-668